Transdermal iontophoresis of the dopamine agonist 5-OH-DPAT in human skin in vitro

Journal of Controlled Release

Volumn 103, Issue 2, 2005, Pages 393-403

  Nugroho, Akhmad Kharis ^a,b   Li, Li ^a   Dijkstra, Durk ^c   Wikström, Håkan ^c   Danhof, Meindert ^a   Bouwstra, Joke A ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b GADJAH MADA UNIVERSITY   (Indonesia)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Current density; Electro repulsion; Parkinson's disease; pH; Skin electric resistance

Indexed keywords

CELLS; CHEMICAL REACTIONS; CURRENT DENSITY; DRUG PRODUCTS; ELECTRIC CURRENTS; PH EFFECTS; SODIUM CHLORIDE;

DERMATOMED HUMAN SKIN (DHS); HUMAN STRATUM CORNEUM (HSC); IONTOPHORETIC DELIVERY; PASSIVE DIFFUSION;

SKIN;

DOPAMINE RECEPTOR STIMULATING AGENT; ROTIGOTINE; SODIUM CHLORIDE;

AQUEOUS SOLUTION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENSITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG TRANSPORT; FEASIBILITY STUDY; HUMAN; IN VITRO STUDY; IONTOPHORESIS; PARKINSON DISEASE; PH; PRIORITY JOURNAL; REDUCTION; STRATUM CORNEUM; TITRIMETRY;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; DOPAMINE AGONISTS; HUMANS; HYDROGEN-ION CONCENTRATION; IONTOPHORESIS; SKIN; SKIN ABSORPTION;

EID: 14844307117     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2004.12.004     Document Type: Article

References (33)

1. A. Lledo Dopamine agonists: the treatment for Parkinson's disease in the XXI century? Parkinsonism Relat. Disord. 7 2000 51 58
2. M. Bollard, J. Caldwell, G.W. Taylor, M. Strolin-Benedetti, and C. Semeraro Pharmacokinetics and disposition of the novel dopamine agonist Z-7760 in rat after intravenous and oral administration Xenobiotica 30 2000 983 991
3. D. Deleu, M.G. Northway, and Y. Hanssens Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease Clin. Pharmacokinet. 41 1904 261 309
4. P.J. Swart, and R.A. de Zeeuw Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats Pharmazie 47 1992 613 615
5. B.H. Sage Iontophoresis Eric W. Smith Howard I. Maibach Percutaneous penetration enhancer 1995 CRC Press 351 368
6. K.S. Wong, C.S. Lu, D.E. Shan, C.C. Yang, T.H. Tsoi, and V. Mok Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease J. Neurol. Sci. 216 2003 81 87
7. A. Luzardo-Alvarez, M.B. Delgado-Charro, and J. Blanco-Mendez Iontophoretic delivery of ropinirole hydrochloride: effect of current density and vehicle formulation Pharm. Res. 18 2001 1714 1720
8. R. Van der Geest, M. Danhof, and H.E. Bodde Iontophoretic delivery of apomorphine: I. In vitro optimization and validation Pharm. Res. 14 1997 1798 1803
9. G.L. Li, M. Danhof, and J.A. Bouwstra Effect of elastic liquid-state vesicle on apomorphine iontophoresis transport through human skin in vitro Pharm. Res. 18 2001 1627 1630
10. G.L. Li, M. Danhof, and J.A. Bouwstra Iontophoretic delivery of apomorphine in vitro: physicochemic considerations Pharm. Res. 18 2001 1509 1513
11. G.L. Li, R. Van der Geest, L. Chanet, E. van Zanten, M. Danhof, and J.A. Bouwstra In vitro iontophoresis of R-apomorphine across human stratum corneum. Structure-transport relationship of penetration enhancement J. Control. Release 84 2002 49 57
12. G.L. Li, M. Danhof, P.M. Frederik, and J.A. Bouwstra Pretreatment with a water-based surfactant formulation affects transdermal iontophoretic delivery of R-apomorphine in vitro Pharm. Res. 20 2003 653 659
13. R. Van der Geest, T. Van Laar, J.M. Gubbens-Stibbe, H.E. Bodde, and M. Danhof Iontophoretic delivery of apomorphine: II. An in vivo study in patients with Parkinson's disease Pharm. Res. 14 1997 1804 1810
14. G.L. Li, Transdermal iontophoretic delivery of R-apomorphine for the treatment of patients with Parkinson's Disease, PhD thesis, Leiden University, Leiden, The Netherlands, 2003.
15. J. Van der Weide, J.B. de Vries, P.G. Tepper, D.N. Krause, M.L. Dubocovich, and A.S. Horn N-0437: a selective D-2 dopamine receptor agonist in in vitro and in vivo models Eur. J. Pharmacol. 147 1988 249 258
16. A.K. Nugroho, G.L. Li, M. Danhof, and J.A. Bouwstra Transdermal iontophoresis of rotigotine across human stratum corneum in vitro: influence of pH and NaCl concentration Pharm. Res. 21 2004 844 850
17. A.K. Nugroho, G.L. Li, A. Grossklaus, M. Danhof, and J.A. Bouwstra Transdermal iontophoresis of rotigotine: influence of concentration, temperature and current density in human skin in vitro J. Control. Release 96 2004 159 167
18. M.P. Seiler, and R. Markstein Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum Mol. Pharmacol. 26 1984 452 457
19. J.D. McDermed, G.M. McKenzie, and H.S. Freeman Synthesis and dopaminergic activity of (±)-, (+)-, and (-)-2-dipropyiamino-5-hydroxy-1,2,3,4- tetrahydronaphthalenel J. Med. Chem. 19 1976 547 549
20. A.S. Horn, P. Tepper, J. Van der Weide, M. Watanabe, D. Grigoriadis, and P. Seeman Synthesis and radioreceptor binding activity of N-0437, a new, extremely potent and selective D2 dopamine receptor agonist Pharm. Weekbl., Sci. 7 1985 208 211
21. N. Rodenhuis, W. Timmerman, H.V. Wikstrom, and D. Dijkstra Thiophene analogs of naphthoxazines and 2-aminotetralins: bioisosteres with improved relative oral bioavailability, as compared to 5-OH-DPAT Eur. J. Pharmacol. 394 2000 255 263
22. R. Van der Geest, M. Danhof, and H.E. Bodde Validation and testing of a new iontophoretic continuous flow through transport cell J. Control. Release 51 1998 85 91
23. N. Kanikkannan, J. Singh, and P. Ramarao In vitro transdermal iontophoretic transport of timolol maleate: effect of age and species J. Control. Release 71 2001 99 105
24. S.Y. Oh, S.Y. Jeong, T.G. Park, and J.H. Lee Enhanced transdermal delivery of AZT (Zidovudine) using iontophoresis and penetration enhancer J. Control. Release 51 1998 161 168
25. D. Marro, R.H. Guy, and M.B. Delgado-Charro Characterization of the iontophoretic permselectivity properties of human and pig skin J. Control. Release 70 2001 213 217
26. J.B. Phipps, and J.R. Gyory Transdermal ion migration Adv. Drug Deliv. Rev. 9 1992 137 176
27. M.B. Delgado-Charro, A.M. Rodriguez-Bayon, and R.H. Guy Iontophoresis of nafarelin: effects of current density and concentration on electrotransport in vitro J. Control. Release 35 1995 35 40
28. A.J. Hoogstraate, V. Srinivasan, S.M. Sims, and W.I. Higuchi Iontophoretic enhancement of peptides: behaviour of leuprolide versus model permeants J. Control. Release 31 1994 41 47
29. J. Hirvonen, and R.H. Guy Iontophoretic delivery across the skin: electroosmosis and its modulation by drug substances Pharm. Res. 14 1997 1258 1263
30. G.L. Li, A. Grossklaus, M. Danhof, and J.A. Bouwstra Iontophoretic R-apomorphine delivery in combination with surfactant pretreatment: in vitro validation studies Int. J. Pharm. 266 2003 61 68
31. J.A. Bouwstra, A. de Graaff, G.S. Gooris, J. Nijsse, J.W. Wiechers, and A.C. van Aelst Water distribution and related morphology in human stratum corneum at different hydration levels J. Invest. Dermatol. 120 2003 750 758
32. D.J. Davies, R.J. Ward, and J.R. Heylings Multi-species assessment of electrical resistance as a skin integrity marker for in vitro percutaneous absorption studies Toxicol. In Vitro 18 2004 351 358
33. V.P. Calabrese, K.A. Lloyd, P. Brancazio, E. Cefali, P. Martin, J.J. Wall, and D. Sica N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism Mov. Disord. 13 1998 768 774